FORMULATION AND EVALUATION OF SOILD LIPID NANOPARTICLES OF SERTRALINE HYDROCHLORIDE
Abstract
Depression is a global affective and common mental disorder, with over 264 million people experiencing it. It is characterized by depressed mood, loss of interest, feelings of guilt or low self-worth, disturbed sleep or appetite, and poor concentration. A new class of colloidal delivery system has been introduced that encompasses a number of advantages over the conventional dosage forms and one of it includes the solid lipid nanoparticles (SLN) with the major advantage of been controlled and site-specific drug delivery. It is made up of a solid core and phospholipid shell having high drug loading to enhance bioavailability. Sertraline hydrochloride is an antidepressant drug used for brain targeting. The main objective of the work was to formulate Sertraline hydrochloride-loaded solid lipid nanoparticles and to screen the effect of formulation with process variables on the performance of these formulated solid lipid nanoparticles. Hot homogenization technique was used to formulate the solid lipid nanoparticles using of 32 factorial designs. The effect of independent variables on the concentration of Poloxamer 188 and Glyceryl monosterate on viscosity and drug release was studied. SLNs containing sertraline hydrochloride were prepared and evaluated. The results depicted F6 as an optimized formulation with an entrapment efficiency of 87.36 ± 1.45% and a drug release of 84.26 ± 1.10%. With the thorough screening study, the enrichment of Sertraline hydrochloride entrapment was attained with good particle size and controlled release. The factorial design confirmed its influence and significance in determining and understanding both formulation and process variables affecting the quality of SLNs.
Keywords:
Sertraline hydrochloride, Solid lipid nanoparticles, Blood Brain Barrier, DepressionDOI
https://doi.org/10.25004/IJPSDR.2021.130206References
Derek R. Prevalence and clinical course of depression: A review. Clin Psychol Rev. 2011; 31:1117–1125. Available from:doi:10.1016/j. cpr.2011.07.004
Zisook S, Lesser I, Stewart J . Effect of age at onset on the course of major depressive disorder. Am J Psychiatry. 2007; 164(10):1539– 1546. Available from: doi: 10.1176/appi.ajp.2007.06101757.
Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive compulsive disorder. Drugs. 1992; 44:604-624. Available from: doi: 10.2165/00003495-199244040- 00007.
Kaur I, Bhandari R. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008; 127(2):97-109. Available from:doi: 10.1016/j.jconrel.2007.12.018.
Carla V, Filomena A. The size of solid lipid nanoparticles: An interpretation from experimental design. Colloids Surf B Biointerfaces. 2011; 84(1):117-130. Available from: doi: 10.1016/j. colsurfb.2010.12.024.
Madan J, Khude P, Dua K. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. Int. J. Pharm. Investig. 2014; 4(2): 60-4. Available from: doi: 10.4103/2230-973X.133047.
Ekambaram P, Sathali A. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011;3:216-20. Available from: doi: 10.4103/0975-1483.83765.
Muk herjee S, Ray S. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349- 358. Available from: doi: 10.4103/0250-474X.57282.
Golnar D, Hamid R M , Preparat ion of S L N- containing Thermoresponsive In-situ Forming Gel as a Controlled Nanoparticle Delivery System and Investigating its Rheological, Thermal and Erosion Behavior. Iran J of Pharm Res. 2015; 14 (2): 347-358.
Khare A, Singh I, Pawar P. Design and Evaluation of Voriconazole Loaded Solid Lipid Nanoparticles for Ophthalmic Application.J Drug Delivery. 2016;1-12. Available from: doi: 10.1155/2016/6590361
Gupta S, Kesarla K. Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability. BioMed Res Int. 2017; 1-18. Available from: doi.org/10.1155/2017/5984014.
Neves A, Queiroz J et al. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol. 2016 : 14. Available from: doi: 10.1186/s12951- 016-0177-x.
Pouton C. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J of Pharm Sci. 2006; 29(3-4 :278–287. Available from: DOI: 10.1186/s12951-016-0177-x.
Kushwaha K. Fabrication and Characterization of Pluronic F68 and Phospholipon 90g Embedded Nanoformulation for Sertraline Delivery: An Optimized Factorial Design Approach and In Vivo Study. Asian J of Pharm Res Dev. 2019; 7(3): 59 -66. Available from: doi.org/10.22270/ajprd.v7i3.505.
Liu C, Wu C, Fang J. Characterization and formulation optimization of solid lipid nanopart icles in vitamin K1 delivery. Drug Dev Ind Pharm. 2010; 36(7):751–761. Available from: doi: 10.3109/03639040903460453
Gupta S, Kesarla R, Chotai N, Misra A, Omri A. Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability. BioMed Res Int. 2017; 1-19. Available from: doi: 10.1155/2017/5984014.
Published
Abstract Display: 821 
PDF Downloads: 583 
